Shared idiotype expression by chronic lymphocytic leukemia and B-cell lymphoma.

Abstract

Antiidiotype (Id) antibodies identify unique determinants within the surface immunoglobulin (Ig) that are present on B-cell tumors. Anti-Ids have been used for diagnosis and therapy of B-cell lymphoma and leukemia. A panel of 29 anti-Id monoclonal antibodies (MoAbs) that recognize shared idiotypes (SIds) on B-cell lymphomas was tested for reactivity with both B-cell leukemias and lymphomas. Ten of 40 (25%) cases of chronic lymphocytic leukemia (CLL) reacted with at least one of the 29 anti-SId MoAbs. Three cases reacted with more than one anti-SId MoAb, but there was no repetitive pattern of a single anti-SId MoAb reacting with a large proportion of CLL cases. In contrast, for B-cell lymphoma, in which 11 of 31 (36%) cases reacted, one anti-SId (B4-1) reacted with five of the positive cases; all were diffuse histology. Restricted anti-SId reactivity may lead to important insights into the etiology of certain B-cell lymphomas. In addition, these anti-SIds may obviate the need to develop "tailor-made" antibodies for individual patients.

• Authors: M Chatterjee, M Barcos, T Han, X L Liu, Z Bernstein, K A Foon
• Journal: Blood (Blood) Vol. 76 Issue 9 Pg. 1825-9 (Nov 01 1990) ISSN: 0006-4971 [Print] United States
• PMID: 2224130 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antibodies, Monoclonal
• Immunoglobulin Idiotypes
• Receptors, Antigen, B-Cell

Topics

• Antibodies, Monoclonal (immunology, therapeutic use)
• Gene Expression
• Humans
• Immunoglobulin Idiotypes (analysis, genetics, immunology)
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, genetics, immunology)
• Lymphoma, B-Cell (drug therapy, genetics, immunology)
• Receptors, Antigen, B-Cell (immunology)